|
Kidney Failure, Chronic
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Objective</b> To examine long term cardiorenal outcomes associated with increased concentrations of creatinine after the start of angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment.<b>Design</b> Population based cohort study using electronic health records from the Clinical Practice Research Datalink and Hospital Episode Statistics.<b>Setting</b> UK primary care, 1997-2014.<b>Participants</b> Patients starting treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers (n=122 363).<b>Main outcome measures</b> Poisson regression was used to compare rates of end stage renal disease, myocardial infarction, heart failure, and death among patients with creatinine increases of 30% or more after starting treatment against those without such increases, and for each 10% increase in creatinine.
|
28279964 |
2017 |
|
Kidney Failure, Chronic
|
0.600 |
Biomarker
|
disease |
BEFREE |
20 patients on angiotensin 1-converting enzyme inhibitor/angiotensin receptor antagonist (ACEI/ATRA) therapy were then compared with another 20 patients not treated with ACEI /ATRA to determine their renal outcome in response to ACEI/ATRA therapy and whether their genetic profile of ACE gene could play a role in determining their outcome to ACEI /ATRA therapy and progression to end-stage renal failure (ESRF).
|
22173253 |
2011 |
|
Kidney Failure, Chronic
|
0.600 |
Biomarker
|
disease |
BEFREE |
End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes.
|
28177196 |
2017 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ACE gene polymorphism does not have a significant effect on the development of ESRD and the prevalence of LVH in patients with ADPKD.
|
14600431 |
2004 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ACE gene polymorphism, left ventricular geometry, and mortality in diabetic patients with end-stage renal disease.
|
15036826 |
2004 |
|
Kidney Failure, Chronic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) have been shown to significantly delay the progression of chronic kidney disease and the onset of ESRD.
|
26995302 |
2016 |
|
Kidney Failure, Chronic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors can remarkably delay the development of ESRD.
|
30128941 |
2019 |
|
Kidney Failure, Chronic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of end-stage renal disease and slow the progression of nephropathy, but they do not appear to decrease all-cause or cardiovascular mortality in people with Type 2 diabetes and proteinuria.
|
31407377 |
2020 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A deletion polymorphism in the angiotensin-converting enzyme (ACE) gene has been reported to be a risk factor for progression to chronic renal failure in immunoglobulin A nephropathy (IgAN).
|
9590186 |
1998 |
|
Kidney Failure, Chronic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Additionally, BPS reduced the levels of MDA while increasing the levels of SOD, ACE activity, and AT1 expression in the renal tissues of CRF rats.
|
30078019 |
2018 |
|
Kidney Failure, Chronic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although angiotensin-converting enzyme inhibition is effective in Alport syndrome patients for slowing progression to end-stage renal disease, it is neither a cure nor an adequate long-term protector.
|
24988067 |
2014 |
|
Kidney Failure, Chronic
|
0.600 |
Therapeutic
|
disease |
RGD |
Although compelling evidence of a beneficial effect exists for the use of angiotensin-converting enzyme inhibitors (ACEIs) and low-protein diets, there is little evidence on whether carbon adsorbent has an effect on retardation of the progression of CRF.
|
14586729 |
2003 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease.
|
16791616 |
2006 |
|
Kidney Failure, Chronic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Armed with the knowledge that ACE overactivity was associated with their disease, we gave what was intended to be a tissue ACE-inhibitory dose of a hydrophobic ACE inhibitor to 800 Caucasian and African-American male patients with hypertension and 200 Caucasian and African-American male patients with chronic renal failure, over a period of 3 years.
|
12396747 |
2002 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
By univariate analysis, presence of hypertension and degree of proteinuria at diagnosis, and unfavorable histology but not ACE genotype, was significantly associated with progression to ESRD.
|
12172761 |
2002 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Compared with DPP4i nonusers, DPP4i users had a lower risk of ESRD (hazard ratio, 0.81; 95% CI, 0.70-0.94; P=.04) and all-cause mortality (hazard ratio, 0.28; 95% CI, 0.23-0.34; P<.001) after adjustments for CKD, advanced CKD, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.
|
30343892 |
2018 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Comparing patients with ESRD (IgAN-ESRD) and those without ESRD (IgAN-non ESRD), there was a significant increase only in the ACE DD genotype (P < 0.05) among the four gene polymorphisms.
|
21163122 |
2010 |
|
Kidney Failure, Chronic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conventional management consists of pain relief with analgesic drugs, nephroprotection (angiotensin converting enzyme inhibitors and angiotensin receptors blockers) and antiarrhythmic agents, whereas dialysis or renal transplantation are available for patients experiencing end-stage renal failure.
|
21092187 |
2010 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Faster progression to ESRD is associated with the ACE genotype when the total population with ESRD and with the AGT genotype when patients with glomerulonephritis are considered.
|
11422735 |
2001 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
For renal outcomes, ARBs significantly reduced the risk of ESRD by 23% (odds ratio 0.77, 95%CI 0.65-0.92), while ACE inhibitors were not associated with a decreased risk of ESRD (0.69, 0.43-1.10).
|
29794446 |
2018 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Given the effect of angiotensin-converting enzyme inhibitors on the progression of both diabetic and non-diabetic renal disease, we hypothesized that the polymorphisms of NAD(P)H oxidase are associated with development of end-stage renal disease (ESRD).
|
16215641 |
2005 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, ID polymorphism of the ACE gene plays an important role in the pathogenesis of vascular access thrombosis in subjects undergoing hemodialysis for chronic renal failure.
|
11525534 |
2001 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the ACE gene that controls RAS response may influence the development and progression of nephropathy to ESRD.
|
15012717 |
2003 |
|
Kidney Failure, Chronic
|
0.600 |
Biomarker
|
disease |
BEFREE |
In nondiabetic proteinuric nephropathies, the ACE I/D polymorphism does not predict disease progression, but is a strong predictor of ACE inhibition-associated renoprotection in that proteinuria, DeltaGFR, and progression to ESRD are effectively reduced in patients with the DD, but not in those with the II or ID genotype.
|
10620209 |
2000 |
|
Kidney Failure, Chronic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this large series of ADPKD patients, we found no effect of the ACE (I/D) polymorphism on the age at ESRD, either alone or in combination with the G460W polymorphism of ADD.
|
13679477 |
2003 |